Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug.

Bauman, Jonathan N; Frederick, Kosea S; Sawant, Aarti; Walsky, Robert L; Cox, Loretta M; Obach, Ronald S; Kalgutkar, Amit S

Bauman, Jonathan N; Frederick, Kosea S; Sawant, Aarti; Walsky, Robert L; Cox, Loretta M; Obach, Ronald S; Kalgutkar, Amit S.

Affiliation

Bauman JN; Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340, USA.

Drug Metab Dispos ; 36(6): 1016-29, 2008 Jun.

Article in En | MEDLINE | ID: mdl-18332080

Subject(s)

Antidepressive Agents, Second-Generation/metabolism; Antipsychotic Agents/metabolism; Piperazines/metabolism; Quinolones/metabolism; Triazoles/metabolism; Aripiprazole; Cyanides/metabolism; Cytochrome P-450 CYP2D6/metabolism; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A/metabolism; Cytochrome P-450 CYP3A Inhibitors; Glutathione/metabolism; Humans; Microsomes, Liver/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Piperazines / Antipsychotic Agents / Triazoles / Quinolones / Antidepressive Agents, Second-Generation Limits: Humans Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2008 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google